On September 17, Natera rose 3.18% in regular trading, trading at $355.63/share, with turnover of $34.66 million.

On the news front, multiple investment banks recently raised their price targets on Natera in quick succession. UBS significantly raised its target from $290 to $435 while maintaining a Buy rating, and Rothschild & Co Redburn initiated coverage with a Buy rating and a $385 price target. Earlier, RBC Capital also lifted its target from $275 to $350, maintaining an Outperform rating. The consensus mean target now stands at approximately $344.

The upgraded outlooks are underpinned by a series of commercial milestones for Natera's Signatera molecular residual disease test, including FDA approval as a companion diagnostic in muscle-invasive bladder cancer, regulatory clearance from Japan's PMDA for colorectal cancer use, and EU IVDR Class C certification across multiple solid tumor types. Additionally, the company's Q2 revenue of $752.8 million significantly beat the $661.2 million estimate, prompting management to raise full-year revenue guidance to $2.85–$2.91 billion, above the $2.80 billion consensus.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)